Beneficial Ownership Report · SCHEDULE 13G/A
Emergent Biosolutions, Inc.
EBSNYSEEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Emergent BioSolutions Inc.
- Company CIK
- 0001367644
- Street
- 300 PROFESSIONAL DR
- City
- GAITHERSBURG
- State / country code
- MD
- Postal code
- 20879
Statement details
- Amendment number
- 1
- Security class
- Common Stock, par value $0.001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- Oak Hill Advisors LP
- Citizenship / organization
- DE
- Reporting person type
- IA · PN
- Aggregate amount owned
- 4,014,015.00
- Percent of class
- 7.5
- Sole voting power
- 4,014,015.00
- Shared voting power
- 0.00
- Sole dispositive power
- 4,014,015.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
- Comments
- Includes 2,500,000 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.
Item 1
Issuer
Emergent BioSolutions Inc.
Principal executive office address
300 Professional Drive, Gaithersburg, MD 20879
Item 2
Citizenship
OHA is a Delaware limited partnership.
Filing person
This Schedule 13G is being filed on behalf of Oak Hill Advisors, L.P., a Delaware limited partnership ("OHA" or, the "Reporting Person"), as investment adviser to certain funds and client accounts (directly or through an affiliate) (together, the "Oak Hill Funds"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Emergent BioSolutions Inc. (the "Company"), and the shares of Common Stock issuable upon exercise of warrants, directly held by the Oak Hill Funds. OHA is a subsidiary business of T. Rowe Price Associates, Inc. ("TRP"). OHA's beneficial ownership does not include any shares that may be beneficially owned by TRP. Glenn R. August, a United States citizen, is the Founder and Chief Executive Officer of OHA. Any disclosures herein with respect to persons other than the Reporting Person are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by the Reporting Person as to beneficial ownership of the securities reported herein.
Principal business or residence address
The address of the business office of the Reporting Person is One Vanderbilt Avenue, 16th Floor, New York, New York 10017.
Item 3
Not applicable indication
N
Type of filing person
IA
Item 4
Percent of class
7.5%
Amount beneficially owned
The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 51,273,336 shares of Common Stock outstanding as of July 30, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026, and assumes the exercise of the warrants reported herein.
Sole voting power
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
Shared voting power
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
Sole dispositive power
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
Shared dispositive power
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
See Item 2(a). The Oak Hill Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- Oak Hill Advisors LP
- Signed
- /s/ William H. Bohnsack, Jr.
- Title
- William H. Bohnsack, Jr., Authorized Signatory
- Date
- 11/16/2026
Company context
Joseph Papa President and Chief Executive Officer Richard Lindahl EVP, Chief Financial Officer and Treasurer Jessica Perl SVP, General Counsel and Corporate Secretary Paul Williams SVP, Products Business Coleen Glessner EVP, Quality, Ethics and Compliance Simon Lowry, M.D. Chief Medical Officer, Head of Research and Development Stephanie Duatschek SVP, Chief Strategy and Transformation Officer Michelle Pepin SVP, Chief Human Resources Officer Bill Hartzel SVP, Manufacturing and Bioservices Emergent’s Executive Management Team
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by AMERICAN CENTURY INVESTMENT MANAGEMENT INC regarding Emergent BioSolutions Inc.Nov 16, 2026
- Other EventsNov 4, 2026
- 10-Q filingNov 3, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureNov 2, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 16, 2026